We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

29 hedge funds and large institutions have $408K invested in Aspire Biopharma Warrant in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

7% more funds holding

Funds holding: 27 → 29 (+2)

39% less capital invested

Capital invested by funds: $667K → $408K (-$259K)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
29
Holders Change
+2
Holders Change %
+7.41%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
1
Reduced
2
Closed
3
Calls
$12K
Puts
–
Net Calls
+$12K
Net Calls Change
-$7K

Top Buyers

Rank Fund Capital Flow
1
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$25.5K
2
Nomura Holdings
Nomura Holdings
Japan
+$7.41K
3
VAS
VR Advisory Services
Cayman Islands
+$4.92K
4
FTUS
Flow Traders U.S.
New York
+$15
5
Osaic Holdings
Osaic Holdings
Arizona
+$2

Top Sellers

Rank Fund Capital Flow
1
SC
Sculptor Capital
New York
-$94.1K
2
AIMCA
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
-$16.9K
3
PC
Periscope Capital
Ontario, Canada
-$14K
4
RFA
Reyes Financial Architecture
California
-$4
5
FFA
Farther Finance Advisors
California
-$1
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$46.9K – – –
HCM
2
Highbridge Capital Management
New York
$46.7K – – –
SCM
3
Saba Capital Management
New York
$44.2K – – –
LA
4
Linden Advisors
New York
$40.5K – – –
AC
5
Aristeia Capital
Connecticut
$30.6K – – –
Toronto Dominion Bank
6
Toronto Dominion Bank
Ontario, Canada
$23.1K +$25.5K +516,845 New
SC
7
Sculptor Capital
New York
$22.5K -$94.1K -1,905,000 -79%
Verition Fund Management
8
Verition Fund Management
Connecticut
$19.3K – – –
Barclays
9
Barclays
United Kingdom
$15.6K – – –
CS
10
Clear Street
New York
$14.8K – – –
TCA
11
Taconic Capital Advisors
New York
$13.4K – – –
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$8.94K – – –
WAM
13
Wolverine Asset Management
Illinois
$8.76K – – –
CCM
14
Context Capital Management
California
$7.82K – – –
MTCM
15
Mint Tower Capital Management
Netherlands
$7K – – –
Nomura Holdings
16
Nomura Holdings
Japan
$6.75K +$7.41K +150,000 New
PAMP
17
Polar Asset Management Partners
Ontario, Canada
$6.23K – – –
AC
18
Athos Capital
Hong Kong
$6K – – –
PC
19
Periscope Capital
Ontario, Canada
$5.59K -$14K -283,643 -69%
LP
20
LMR Partners
United Kingdom
$5.59K – – –
WA
21
Whitebox Advisors
Minnesota
$5.31K – – –
CSD
22
Clear Street Derivatives
New York
$4.74K – – –
JP Morgan Chase
23
JP Morgan Chase
New York
$4.47K – – –
VAS
24
VR Advisory Services
Cayman Islands
$4.45K +$4.92K +99,692 New
LIA
25
Limestone Investment Advisors
New York
$3.35K +$3.71K +75,000 New
1
2

ASBPW Hedge Fund Activity: Q2 2025 in Review

29 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q2 2025, worth a combined $408K — down 39% from $667K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ASBPW positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $25.5K. The largest seller was Sculptor Capital, cutting an estimated $94.1K.

  • 29 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q2 2025, up from 27 in Q1 2025.
  • Funds reported $408K of Aspire Biopharma Warrant stock for Q2 2025, down 39% quarter-over-quarter.
  • 6 funds opened new Aspire Biopharma Warrant positions in Q2 2025 and 3 closed out, a net change of +3 holders.
  • The largest Aspire Biopharma Warrant buyer in Q2 2025 was Toronto Dominion Bank, an estimated $25.5K added.
  • The largest Aspire Biopharma Warrant seller in Q2 2025 was Sculptor Capital, an estimated $94.1K sold.

Based on aggregated 13F filings for Q2 2025.